Mohammad Hussain, MD
Neurology · Jefferson City, TNNPI 1699773747
Payments from drug & device makers
Across 1,019 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- AbbVie$2K
- Biogen$1K
- Livanova USA, Inc.$1K
- Neurelis, Inc.$1K
- Novartis$1K
- plus $10K from 50 others
What the payments were for
- Travel & lodging$1,5848%
- Food & beverage$17,18691%
- Education$1181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$960
- WEB$871
- UBRELVY$248
- BRIUMVI$138
- AIMOVIG$116
How this compares
$18,888 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 17 | $949,014 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 27 | $705,806 |
| OcrevusOcrelizumab | 15 | $608,486 |
| Kesimpta PenOfatumumab | 54 | $482,355 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 34 | $409,907 |
| ZeposiaOzanimod Hydrochloride | 22 | $216,868 |
| Nurtec OdtRimegepant Sulfate | 92 | $147,351 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $123,219 |
| QuliptaAtogepant | 98 | $110,236 |
| TysabriNatalizumab | 13 | $107,271 |
| Teriflunomide | 36 | $101,853 |
| UbrelvyUbrogepant | 80 | $94,598 |
| BotoxOnabotulinumtoxina | 60 | $77,961 |
| AptiomEslicarbazepine Acetate | 39 | $73,427 |
| GlatopaGlatiramer Acetate | 23 | $59,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $994 | $949,01417 claims |
| PfizerOctagam, Nurtec Odt, Eliquis | $397 | $895,397173 claims |
| Grifols USA, LLCGamunex-C | $187 | $409,90734 claims |
| AbbVieQulipta, Ubrelvy, Botox, Namzaric | $1,627 | $304,201265 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $42 | $216,86822 claims |
| CSL BehringPrivigen | $41 | $123,21912 claims |
| BiogenTysabri | $1,465 | $107,27113 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $289 | $73,42739 claims |
| UCB, Inc.Briviact, Neupro | $2,221 | $71,97558 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $133 | $55,24230 claims |
| Eisai Inc.Fycompa | $809 | $39,62132 claims |
| Neurelis, Inc.Valtoco | $1,167 | $14,81811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.
Other neurology in Jefferson City
- Lee SteinCordova$22.6M
- Sibyl WrayKnoxville$21.6M
- Lora McGillMemphis$7.5M
- Thomas ArnoldCordova$5.5M
- Daniel ClaassenNashville$3.5M
- Samuel HunterSpring Hill$2.9M
- Randall TrudellKnoxville$2.8M
- Oleksandra DrynCordova$2.8M
- Siddharama PawateNashville$2M
- Anthony NicholasMemphis$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.